RESUMEN
Curcumin and artemisinin are commonly used in traditional East Asian medicine. In this study, we investigated the inhibitory effects of these active compounds on xanthine oxidase (XO) using allopurinol as a control. XO was purified from the serum of arthritis patients through ammonium sulfate precipitation (65%) and ion exchange chromatography on diethylaminoethyl (DEAE)-cellulose. The specific activity of the purified enzyme was 32.5 U/mg protein, resulting in a 7-fold purification with a yield of 66.8%. Molecular docking analysis revealed that curcumin had the strongest interaction energy with XO, with a binding energy of -9.28 kcal/mol. The amino acid residues Thr1077, Gln762, Phe914, Ala1078, Val1011, Glu1194, and Ala1079 were located closer to the binding site of curcumin than artemisinin, which had a binding energy of -7.2 kcal/mol. In vitro inhibition assays were performed using nanocurcumin and artemisinin at concentrations of 5, 10, 15, 20, and 25 µg/mL. Curcumin inhibited enzyme activity by 67-91%, while artemisinin had a lower inhibition ratio, which ranged from 40-70% compared to allopurinol as a control.
Asunto(s)
Artemisininas , Artritis , Curcumina , Xantina Oxidasa , Xantina Oxidasa/antagonistas & inhibidores , Xantina Oxidasa/sangre , Curcumina/química , Curcumina/farmacología , Artemisininas/química , Artemisininas/farmacología , Humanos , Artritis/sangre , Artritis/enzimología , Simulación del Acoplamiento Molecular , Alopurinol/química , Alopurinol/farmacología , Unión ProteicaRESUMEN
Destruction of the cartilage matrix in joints is an important feature of arthritis. Proteolytic degradation of cartilage glycoproteins can contribute to the loss of matrix integrity. Human inter-α-inhibitor (IαI), which stabilizes the extracellular matrix, is composed of the light-chain serine proteinase inhibitor bikunin and two homologous heavy chains (HC1 and HC2) covalently linked through chondroitin 4-sulfate. Inflammation promotes the transfer of HCs from chondroitin 4-sulfate to hyaluronan by tumor necrosis factor-stimulated gene-6 protein (TSG-6). This reaction generates a covalent complex between the heavy chains and hyaluronan that can promote leukocyte invasion. This study demonstrates that both IαI and the HC-hyaluronan complex are substrates for the extracellular matrix proteases ADAMTS-5 and matrix metalloprotease (MMP) -3, -7, and -13. The major cleavage sites for all four proteases are found in the C terminus of HC2. ADAMTS-5 and MMP-7 displayed the highest activity toward HC2. ADAMTS-5 degradation products were identified in mass spectrometric analysis of 29 of 33 arthropathic patients, indicating that ADAMTS-5 cleavage occurs in synovial fluid in arthritis. After cleavage, free HC2, together with TSG-6, is able to catalyze the transfer of heavy chains to hyaluronan. The release of extracellular matrix bound HC2 is likely to increase the mobility of the HC2/TSG-6 catalytic unit and consequently increase the rate of the HC transfer reaction. Ultimately, ADAMTS-5 cleavage of HC2 could alter the physiological and mechanical properties of the extracellular matrix and contribute to the progression of arthritis.
Asunto(s)
Proteína ADAMTS5/metabolismo , alfa-Globulinas/metabolismo , Artritis/enzimología , Líquido Sinovial/enzimología , Proteína ADAMTS5/genética , alfa-Globulinas/química , alfa-Globulinas/genética , Secuencias de Aminoácidos , Artritis/genética , Artritis/metabolismo , Matriz Extracelular/enzimología , Matriz Extracelular/genética , Matriz Extracelular/metabolismo , Humanos , Ácido Hialurónico/metabolismo , Metaloproteinasa 13 de la Matriz/genética , Metaloproteinasa 13 de la Matriz/metabolismo , Metaloproteinasa 3 de la Matriz/genética , Metaloproteinasa 3 de la Matriz/metabolismo , Metaloproteinasa 7 de la Matriz/genética , Metaloproteinasa 7 de la Matriz/metabolismo , Líquido Sinovial/metabolismoRESUMEN
Phospholipase A2s (PLA2) play a key role in generation of eicosanoids. Cytosolic PLA2α (cPLA2α) is constitutively expressed in most cells, whereas IIA secreted PLA2 (sPLA2-IIA) is induced during inflammation and is present at high levels in the synovial fluid of rheumatoid arthritis patients. In mice, both cPLA2α and sPLA2-IIA have been implicated in autoimmune arthritis; however, the respective contribution of these two enzymes to the pathogenesis and production of eicosanoids is unknown. We evaluated the respective role of cPLA2α and sPLA2-IIA with regard to arthritis and eicosanoid profile in an in vivo model of arthritis. While arthritis was most severe in mice expressing both enzymes, it was abolished when both cPLA2α and sPLA2-IIA were lacking. cPLA2α played a dominant role in the severity of arthritis, although sPLA2-IIA sufficed to significantly contribute to the disease. Several eicosanoids were modulated during the course of arthritis and numerous species involved sPLA2-IIA expression. This study confirms the critical role of PLA2s in arthritis and unveils the distinct contribution of cPLA2α and sPLA2-IIA to the eicosanoid profile in arthritis.
Asunto(s)
Artritis/metabolismo , Eicosanoides/biosíntesis , Fosfolipasas A2 Grupo II/metabolismo , Fosfolipasas A2 Grupo IV/metabolismo , Animales , Artritis/enzimología , Femenino , Regulación Enzimológica de la Expresión Génica , Fosfolipasas A2 Grupo II/genética , Fosfolipasas A2 Grupo IV/genética , Inflamación/enzimología , Lipidómica , RatonesRESUMEN
It was studied the frequency of cells with cytogenetic abnormalities in the synovial fluid cells of the knee joint in patients of different age groups suffering from chronic arthritis associated with Lyme borreliosis (CAALB) or post-traumatic arthritis (PTA), depending on the polymorphism of the GSTM1 gene of glutathione-S-transferase. The study included 135 residents of the north of the Tomsk and Tyumen regions, 68 of whom suffered from CAALB, and the rest of the 67 patients who made up the control group were diagnosed with PTA. The results of this study have demonstrated that there are significant age-related differences in the frequency of cytogenetic abnormalities of the synovial fluid cells of the knee joint between young and elderly patients of СAALB. The integrative assessment of clinical and cytogenetic parameters in the group of elderly СAALB patients with mutant GSTM1 (0/0) allele, as compared with the other groups, enable to conclude that there are significant positive correlations between the indices of the severity disruption of articular locomotor function and the frequency of synovial fluid cells with trisomy of chromosome 7.
Asunto(s)
Artritis/enzimología , Aberraciones Cromosómicas , Glutatión Transferasa/genética , Articulación de la Rodilla , Polimorfismo Genético , Líquido Sinovial/citología , Membrana Sinovial/citología , Factores de Edad , Anciano , Artritis/genética , Artritis/microbiología , Artritis/patología , Humanos , Enfermedad de Lyme/complicaciones , Siberia , Líquido Sinovial/enzimologíaRESUMEN
OBJECTIVE: Invariant natural killer T (iNKT) cells regulate collagen-induced arthritis (CIA) when activated by their potent glycolipid ligand, alpha-galactosylceramide (α-GalCer). Glucose-6-phosphate isomerase (GPI)-induced arthritis is a closer model of human rheumatoid arthritis based on its association with CD4+ T cells and cytokines such as TNF-α and IL-6 than CIA. Dominant T cell epitope peptide of GPI (GPI325-339) can induce arthritis similar to GPI-induced arthritis. In this study, we investigated the roles of activation of iNKT cells by α-GalCer in GPI peptide-induced arthritis. METHODS: Arthritis was induced in susceptible DBA1 mice with GPI peptide and its severity was assessed clinically. The arthritic mice were treated with either the vehicle (DMSO) or α-GalCer. iNKT cells were detected in draining lymph nodes (dLNs) by flow cytometry, while serum anti-GPI antibody levels were measured by enzyme-linked immunosorbent assay. To evaluate GPI peptide-specific cytokine production from CD4+ T cells, immunized mice were euthanized and dLN CD4+ cells were re-stimulated by GPI-peptide in the presence of antigen-presenting cells. RESULTS: α-GalCer induced iNKT cell expansion in dLNs and significantly decreased the severity of GPI peptide-induced arthritis. In α-GalCer-treated mice, anti-GPI antibody production (total IgG, IgG1, IgG2b) and IL-17, IFN-γ, IL-2, and TNF-α produced by GPI peptide-specific T cells were significantly suppressed at day 10. Moreover, GPI-reactive T cells from mice immunized with GPI and α-GalCer did not generate any cytokines even when these cells were co-cultured with APC from mice immunized with GPI alone. In vitro depletion of iNKT cells did not alter the suppressive effect of α-GalCer on CD4+ T cells. CONCLUSION: α-GalCer significantly suppressed GPI peptide-induced arthritis through the suppression of GPI-specific CD4+ T cells.
Asunto(s)
Artritis/etiología , Linfocitos T CD4-Positivos/metabolismo , Galactosilceramidas/metabolismo , Glucosa-6-Fosfato Isomerasa/metabolismo , Glucolípidos/metabolismo , Células Asesinas Naturales/inmunología , Animales , Artritis/enzimología , Artritis/metabolismo , Citocinas/sangre , Ligandos , Activación de Linfocitos , Masculino , Ratones , Ratones Endogámicos DBARESUMEN
The family of matrix metalloproteinases (MMPs) comprises 24 multidomain enzymes with a zinc-dependent activity. Their structural diversity over the archetypal domain organization confers variable biological function to these molecules ranging from cellular homeostasis and control of tissue turnover to implication in multiple pathological conditions such as inflammation, arthritis, cardiovascular disease and cancer. MMP expression and activity exhibits high tissue-species- and signal-specificity and involves multiple regulatory mechanisms that co-ordinate zymogen activation, endogenous inhibition and gene transcription. In this article, we provide an overview of the molecular mechanisms that regulate MMPs gene expression at transcriptional and post-transcriptional level through integration of signals from multiple pathways to cis-acting elements present in MMP promoters, epigenetic modifications, mRNA stability mechanisms and microRNA modulation. Loss of MMP activity through mutations and single nucleotide polymorphisms is further discussed in the context of disease susceptibility.
Asunto(s)
Metaloproteinasas de la Matriz/genética , Secuencia de Aminoácidos , Animales , Artritis/enzimología , Artritis/metabolismo , Regulación Enzimológica de la Expresión Génica , Humanos , Inflamación/enzimología , Inflamación/metabolismo , Metaloproteinasas de la Matriz/metabolismo , MicroARNs/metabolismo , Neoplasias/enzimología , Neoplasias/metabolismo , ARN Mensajero/metabolismoRESUMEN
This work is to investigate the levels of human xanthine oxidoreductase (HXOR), its antibodies, and microorganisms in synovial fluid of patients with untreated rheumatoid joint diseases. Synovial fluids were collected from sixty-four patients with rheumatoid joint diseases. Sixty-four age-matched individuals were included as control. Xanthine oxidoreductase (XOR) proteins level and anti-XOR antibodies were determined in the blood and synovial fluid, using human XOR as antigen, by enzyme-linked immunosorbent (ELISA) assay. Synovial fluids were cultured for bacteria and fungi. The titers of XOR protein in the synovial fluid of patients with rheumatoid arthritis were 90.43 ± 23.37 µg/ml (mean ± SD, n = 29) and up to 62.42 ± 8.74 µg/ml (mean ± SD, n = 35) in other joint inflammation. Anti-HXOR antibodies titers in patients were 167.72 ± 23.64 µg/ml, n = 64, which was significantly higher in rheumatoid arthritis patients. The results indicated that anti-HXOR antibodies in synovial fluids have a protective role as high concentrations against XOR were detected in inflammatory arthritis. These antibodies play a role in eliminating XOR from synovial fluids. However, immune complex formation could activate complement and participate in propagating the inflammatory cycle. Synovial aspirate ordinary microbial cultures were negative for any bacteria or fungi, but that does not exclude organisms of special culture requirements.
Asunto(s)
Artritis Reumatoide , Artritis , Autoanticuerpos/análisis , Bacterias/aislamiento & purificación , Hongos/aislamiento & purificación , Líquido Sinovial , Xantina Deshidrogenasa/análisis , Xantina Deshidrogenasa/inmunología , Adulto , Complejo Antígeno-Anticuerpo/análisis , Artritis/sangre , Artritis/enzimología , Artritis/inmunología , Artritis/microbiología , Artritis Reumatoide/sangre , Artritis Reumatoide/enzimología , Artritis Reumatoide/inmunología , Artritis Reumatoide/microbiología , Estudios de Casos y Controles , Ensayo de Inmunoadsorción Enzimática , Humanos , Inmunodifusión , Jordania , Persona de Mediana Edad , Factor Reumatoide/sangre , Líquido Sinovial/enzimología , Líquido Sinovial/inmunología , Líquido Sinovial/microbiologíaRESUMEN
Cyclooxygenase-2 (COX-2) is intimately involved in symptoms of arthritis while dietary n-3 polyunsaturated fatty acids (PUFA) are thought to be beneficial. In these experiments, using both bovine and human in vitro systems that mimic features of arthritis, we show that the n-3 PUFA eicosapentaenoic acid (EPA) is able to reduce mRNA and protein levels of COX-2. Activity, as assessed through prostaglandin E(2) formation, was also reduced in a dose-dependent manner. These effects of EPA contrasted noticeably with the n-6 PUFA, arachidonic acid. The data provide direct evidence for a molecular mechanism by which dietary n-3 PUFA, such as EPA, can reduce inflammation and, hence, associated symptoms in arthritis.
Asunto(s)
Artritis/dietoterapia , Artritis/enzimología , Ciclooxigenasa 2/metabolismo , Ácidos Grasos Omega-3/farmacología , Ácidos Grasos Omega-6/farmacología , Animales , Artritis/patología , Cartílago Articular/efectos de los fármacos , Cartílago Articular/enzimología , Cartílago Articular/patología , Bovinos , Células Cultivadas , Ciclooxigenasa 2/biosíntesis , Inhibidores de la Ciclooxigenasa 2/farmacología , Inhibidores de la Ciclooxigenasa 2/uso terapéutico , Grasas de la Dieta/farmacología , Grasas de la Dieta/uso terapéutico , Ácidos Grasos Omega-3/uso terapéutico , Ácidos Grasos Omega-6/uso terapéutico , HumanosRESUMEN
Leukotrienes (LTs) are signaling molecules derived from arachidonic acid that initiate and amplify innate and adaptive immunity. In turn, how their synthesis is organized on the nuclear envelope of myeloid cells in response to extracellular signals is not understood. We define the supramolecular architecture of LT synthesis by identifying the activation-dependent assembly of novel multiprotein complexes on the outer and inner nuclear membranes of mast cells. These complexes are centered on the integral membrane protein 5-Lipoxygenase-Activating Protein, which we identify as a scaffold protein for 5-Lipoxygenase, the initial enzyme of LT synthesis. We also identify these complexes in mouse neutrophils isolated from inflamed joints. Our studies reveal the macromolecular organization of LT synthesis.
Asunto(s)
Araquidonato 5-Lipooxigenasa/metabolismo , Proteínas Portadoras/metabolismo , Leucotrienos/biosíntesis , Proteínas de la Membrana/metabolismo , Complejos Multiproteicos/análisis , Membrana Nuclear/metabolismo , Proteínas Activadoras de la 5-Lipooxigenasa , Animales , Artritis/enzimología , Artritis/metabolismo , Proteínas de la Membrana/análisis , Ratones , Células Mieloides/química , Células Mieloides/metabolismo , Neutrófilos/química , Neutrófilos/metabolismo , Membrana Nuclear/químicaRESUMEN
Inhibition of collagen fragment generation in canine cranial cruciate ligament (CCL) explant cultures by the matrix metalloprotease inhibitor (6-demethyl)-6-deoxy-4-dedimethylamino tetracycline (COL-3) was studied. Cranial cruciate ligament specimens were collected from dogs with inflammatory stifle arthritis/CCL rupture and dogs with normal stifles. Explant cultures from each CCL specimen included one COL-3 treated explant and a baseline control; explants from 12 ruptured CCLs were prepared in triplicate and a protease inhibitor cocktail positive control was used. Explant supernatants were analyzed for generation of collagen fragments after two days. Treatment of ruptured CCL explants with 10(-4)M COL-3 decreased generation of collagen fragments. The extent of this inhibition was increased in explants treated with a protease inhibitor cocktail. Generation of collagen fragments was increased in ruptured CCLs, when compared with intact CCLs. It is concluded that generation of collagen fragments was increased in pathological ruptured CCL explants. This degradation could be significantly inhibited in vitro by 10(-4)M COL-3.
Asunto(s)
Lesiones del Ligamento Cruzado Anterior , Ligamento Cruzado Anterior/metabolismo , Artritis/veterinaria , Colágeno/metabolismo , Perros , Metaloproteinasas de la Matriz/metabolismo , Inhibidores Tisulares de Metaloproteinasas/farmacología , Animales , Ligamento Cruzado Anterior/enzimología , Ligamento Cruzado Anterior/patología , Artritis/enzimología , Artritis/metabolismo , Artritis/patología , Perros/lesiones , Perros/metabolismo , Femenino , Masculino , Rotura/veterinaria , Rodilla de Cuadrúpedos/metabolismo , Técnicas de Cultivo de TejidosRESUMEN
Despite decades of research, only a very limited number of matrix metalloproteinase (MMP) inhibitors have been successful in clinical trials of arthritis. One of the central problems associated with this failure may be our inability to monitor the local activity of proteases in the joints since the integrity of the extracellular matrix results from an equilibrium between noncovalent, 1:1 stoichiometric binding of protease inhibitors to the catalytic site of the activated forms of the enzymes. In the present work, we have measured by flow cytometry the net proteolytic activity in synovial fluids (SF) collected from 95 patients with osteoarthritis and various forms of inflammatory arthritis, including rheumatoid arthritis, spondyloarthropathies, and chronic juvenile arthritis. We found that SF of patients with inflammatory arthritis had significantly higher levels of proteolytic activity than those of osteoarthritis patients. Moreover, the overall activity in inflammatory arthritis patients correlated positively with the number of infiltrated leukocytes and the serum level of C-reactive protein. No such correlations were found in osteoarthritis patients. Members of the MMP family contributed significantly to the proteolytic activity found in SF. Small-molecular-weight MMP inhibitors were indeed effective for inhibiting proteolytic activity in SF, but their effectiveness varied greatly among patients. Interestingly, the contribution of MMPs decreased in patients with very high proteolytic activity, and this was due both to a molar excess of tissue inhibitor of MMP-1 and to an increased contribution of other proteolytic enzymes. These results emphasize the diversity of the MMPs involved in arthritis and, from a clinical perspective, suggest an interesting alternative for testing the potential of new protease inhibitors for the treatment of arthritis.
Asunto(s)
Artritis/metabolismo , Colagenasas/metabolismo , Citometría de Flujo , Péptido Hidrolasas/metabolismo , Líquido Sinovial/enzimología , Artritis/sangre , Artritis/enzimología , Artritis/patología , Artritis Juvenil/enzimología , Artritis Juvenil/metabolismo , Artritis Reumatoide/enzimología , Artritis Reumatoide/metabolismo , Proteína C-Reactiva/metabolismo , Humanos , Leucocitos/patología , Metaloproteinasa 9 de la Matriz/metabolismo , Osteoartritis/enzimología , Osteoartritis/metabolismo , Espondiloartropatías/enzimología , Espondiloartropatías/metabolismo , Inhibidor Tisular de Metaloproteinasa-1/metabolismoRESUMEN
There are two cyclooxygenase (COX) genes encoding characterized enzymes, COX-1 and COX-2. Nonsteroidal anti-inflammatory drugs are commonly used as analgesics in inflammatory arthritis, and these often inhibit both cyclooxygenases. Recently, inhibitors of COX-2 have been used in the treatment of inflammatory arthritis, as this isoform is thought to be critical in inflammation and pain. The objective of this study was to determine the effect of COX-1 or COX-2 gene disruption on the development of chronic Freund's adjuvant-induced arthritis and inflammatory pain in male and female mice. The effect of COX-1 or COX-2 gene disruption on inflammatory hyperalgesia, allodynia, inflammatory edema, and arthritic joint destruction was studied. COX-2 knockout mice (COX-2-/-) showed reduced edema and joint destruction in female, but not male, animals. In addition, neither male nor female COX-2-/- mice developed thermal hyperalgesia or mechanical allodynia, either ipsilateral or contralateral to the inflammation. COX-1 gene disruption also reduced inflammatory edema and joint destruction in female, but not male mice, although females of both COX-/- lines did show some bony destruction. There was no difference in ipsilateral allodynia between COX-1 knockout and wild-type animals, but female COX-1-/- mice showed reduced contralateral allodynia compared with male COX-1-/- or wild-type mice. These data show that the gene products of both COX genes contribute to pain and local inflammation in inflammatory arthritis. There are sex differences in some of these effects, and this suggests that the effects of COX inhibitors may be sex dependent.
Asunto(s)
Antiinflamatorios no Esteroideos/farmacología , Artritis/enzimología , Hiperalgesia/etiología , Dolor/enzimología , Prostaglandina-Endoperóxido Sintasas/genética , Caracteres Sexuales , Animales , Artritis/etiología , Ciclooxigenasa 1/genética , Ciclooxigenasa 2/genética , Edema/enzimología , Edema/etiología , Femenino , Inflamación/enzimología , Articulaciones , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Dimensión del DolorRESUMEN
OBJECTIVE: To clarify the effect of interleukin (IL) 18 on cartilage degeneration by studying the profile of IL18 receptor (IL18R) on chondrocytes and the direct effect of IL18 on production of matrix metalloproteinases (MMPs), aggrecanases, and tissue inhibitors of metalloproteinases (TIMPs) in articular chondrocytes. METHODS: Monolayer cultured human articular chondrocytes were isolated from non-arthritic subjects and patients with rheumatoid arthritis or osteoarthritis. Gene expression of IL18, IL18Ralpha, IL18Rbeta, MMPs, and aggrecanases was detected by RT-PCR. Protein levels of IL18Ralpha were analysed by flow cytometry. Protein levels of IL18, MMPs, and TIMPs were measured by ELISA. Aggrecanase-2 mRNA expression was quantitatively analysed by real time RT-PCR. Protein levels of signalling molecules were assayed by western blotting. RESULTS: IL18 mRNA was constitutively expressed in chondrocytes, and was enhanced by IL1beta stimulation. Flow cytometric analysis showed that IL1beta, tumour necrosis factor alpha, and IL18 up regulated IL18Ralpha expression levels. The level of IL18Rbeta mRNA was much lower than that of IL18Ralpha, and was slightly up regulated by IL1beta. In chondrocytes responding to IL18, IL18 (1-100 ng/ml) slightly increased the production of MMP-1, MMP-3, and MMP-13, which was blocked by NF-kappaB inhibitor and p38 mitogen activated protein kinase inhibitor. IL18 up regulated mRNA expression of aggrecanase-2, but not aggrecanase-1. IL18 also slightly stimulated TIMP-1 production?through extracellular signal regulated kinase activation. CONCLUSION: IL18 induces production of MMPs from chondrocytes in inflammatory arthritis. Although the direct effect of IL18 on chondrocytes may not be pivotal for the induction of cartilage degeneration, IL18 seems to play some part in the degradation of articular cartilage in arthritis.
Asunto(s)
Artritis Reumatoide/enzimología , Cartílago Articular/enzimología , Condrocitos/enzimología , Interleucina-18/farmacología , Metaloproteinasas de la Matriz/biosíntesis , Osteoartritis/enzimología , Proteínas ADAM , Proteína ADAMTS5 , Adulto , Anciano , Anciano de 80 o más Años , Artritis/enzimología , Artritis/metabolismo , Artritis/patología , Artritis Reumatoide/metabolismo , Artritis Reumatoide/patología , Cartílago Articular/patología , Células Cultivadas , Condrocitos/efectos de los fármacos , Condrocitos/metabolismo , Ensayo de Inmunoadsorción Enzimática/métodos , Regulación de la Expresión Génica/efectos de los fármacos , Humanos , Interleucina-18/biosíntesis , Interleucina-18/genética , Metaloendopeptidasas/biosíntesis , Metaloendopeptidasas/genética , Persona de Mediana Edad , Osteoartritis/metabolismo , Osteoartritis/patología , ARN Mensajero/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa/métodos , Transducción de Señal , Inhibidor Tisular de Metaloproteinasa-1/biosíntesisRESUMEN
OBJECTIVE: To determine protein and activity levels of matrix metalloproteinases 1 and 3 (MMP-1 and MMP-3) in synovial fluid of patients with knee joint injury, primary osteoarthritis, and acute pyrophosphate arthritis (pseudogout). METHODS: Measurements were done on knee synovial fluid obtained in a cross sectional study of cases of injury (n = 283), osteoarthritis (n = 105), and pseudogout (n = 65), and in healthy controls (n = 35). Activity of MMP-1 and MMP-3 in alpha(2) macroglobulin complexes was measured using specific low molecular weight fluorogenic substrates. ProMMP-1, proMMP-3, and TIMP-1 (tissue inhibitor of metalloproteinase 1) were quantified by immunoassay. RESULTS: Mean levels of proMMP-1, proMMP-3, and TIMP-1 were increased in injury, osteoarthritis, and pseudogout compared with controls. MMP-1 activity was increased in pseudogout and injury groups over control levels, whereas MMP-3 activity was increased only in the pseudogout group. The increase in MMP-1 activity coincided with a decrease in TIMP-1 levels in the injury group. CONCLUSIONS: Patients with joint injury have a persistent increase in proMMP-1 and proMMP-3 in synovial fluid and an increase in activated MMPs, which are not inhibited by TIMP. The differences in activation and inhibition patterns between the study groups are consistent with disease specific patterns of MMP activation and/or inhibition in joint pathology.
Asunto(s)
Artritis/metabolismo , Traumatismos de la Rodilla/metabolismo , Metaloproteinasas de la Matriz/metabolismo , Líquido Sinovial/metabolismo , Enfermedad Aguda , Adulto , Artritis/enzimología , Condrocalcinosis/enzimología , Condrocalcinosis/metabolismo , Estudios Transversales , Femenino , Humanos , Traumatismos de la Rodilla/enzimología , Masculino , Persona de Mediana Edad , Osteoartritis de la Rodilla/enzimología , Osteoartritis de la Rodilla/metabolismo , Líquido Sinovial/enzimología , Inhibidor Tisular de Metaloproteinasa-1/metabolismo , alfa-Macroglobulinas/metabolismoRESUMEN
Aggrecan is the major proteoglycan in cartilage, endowing this tissue with the unique capacity to bear load and resist compression. In arthritic cartilage, aggrecan is degraded by one or more 'aggrecanases' from the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) family of proteinases. ADAMTS1, 8 and 9 have weak aggrecan-degrading activity. However, they are not thought to be the primary aggrecanases because ADAMTS1 null mice are not protected from experimental arthritis, and cleavage by ADAMTS8 and 9 is highly inefficient. Although ADAMTS4 and 5 are expressed in joint tissues, and are known to be efficient aggrecanases in vitro, the exact contribution of these two enzymes to cartilage pathology is unknown. Here we show that ADAMTS5 is the major aggrecanase in mouse cartilage, both in vitro and in a mouse model of inflammatory arthritis. Our data suggest that ADAMTS5 may be a suitable target for the development of new drugs designed to inhibit cartilage destruction in arthritis, although further work will be required to determine whether ADAMTS5 is also the major aggrecanase in human arthritis.
Asunto(s)
Cartílago/enzimología , Endopeptidasas/metabolismo , Metaloendopeptidasas/metabolismo , Proteínas ADAM , Proteína ADAMTS4 , Proteína ADAMTS5 , Agrecanos , Animales , Antígenos/inmunología , Artritis/enzimología , Artritis/genética , Artritis/inmunología , Artritis/metabolismo , Cartílago/efectos de los fármacos , Cartílago/metabolismo , Modelos Animales de Enfermedad , Endopeptidasas/deficiencia , Endopeptidasas/genética , Proteínas de la Matriz Extracelular/metabolismo , Genotipo , Interleucina-1/farmacología , Lectinas Tipo C , Metaloendopeptidasas/deficiencia , Metaloendopeptidasas/genética , Ratones , Ratones Noqueados , Procolágeno N-Endopeptidasa/genética , Procolágeno N-Endopeptidasa/metabolismo , Proteoglicanos/metabolismo , ARN Mensajero/genética , ARN Mensajero/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Técnicas de Cultivo de TejidosRESUMEN
Rheumatoid arthritis (RA) is a common human disease with a prevalence of about 1% in most parts of the world. At the time of symptom onset it is difficult to predict the severity of subsequent disease course. After 2 years joint erosions are seen in most patients, and most patients become clinically disabled within 20 years. A recent meeting at the Kennedy Institute of Rheumatology (Imperial College, London) brought together representatives from several European centres of excellence, to discuss research funded by the EU Framework 5 Quality of Life Programme. This research network combines gene and protein expression profiling with different animal models of RA to identify cells, genes and pathways contributing to arthritis initiation, progression and chronicity. The studies discussed highlight the reality that collaboration between different research groups is the basis of groundbreaking research and, it is hoped, eventual new therapies for RA.
Asunto(s)
Artritis Reumatoide/tratamiento farmacológico , Artritis/genética , Modelos Animales de Enfermedad , Genes/genética , Inhibidores de la Angiogénesis/uso terapéutico , Animales , Artritis/enzimología , Artritis/microbiología , Artritis Experimental/tratamiento farmacológico , Artritis Experimental/etiología , Artritis Experimental/genética , Borrelia burgdorferi/aislamiento & purificación , Infecciones por Chlamydia/complicaciones , Infecciones por Chlamydia/enzimología , Chlamydia trachomatis/enzimología , Chlamydia trachomatis/aislamiento & purificación , Enterobacteriaceae/enzimología , Enterobacteriaceae/aislamiento & purificación , Infecciones por Enterobacteriaceae/complicaciones , Infecciones por Enterobacteriaceae/enzimología , Unión Europea , Perfilación de la Expresión Génica/métodos , Enfermedad de Lyme/complicaciones , Ratones , Ratones Endogámicos DBA , Reino UnidoRESUMEN
Cathepsin B is a papain-family cysteine protease that is normally located in lysosomes, where it is involved in the turnover of proteins and plays various roles in maintaining the normal metabolism of cells. This protease has been implicated in pathological conditions, e.g., tumor progression and arthritis. In disease conditions, increases in the expression of cathepsin B occur at both the gene and protein levels. At the gene level, the altered expression results from gene amplification, elevated transcription, use of alternative promoters and alternative splicing. These molecular changes lead to increased cathepsin B protein levels and in turn redistribution, secretion and increased activity. Here we focus on the molecular regulation of cathepsin B and attendant implications for tumor progression and arthritis. The potential of cathepsin B as a therapeutic target is also discussed.
Asunto(s)
Artritis/enzimología , Catepsina B/genética , Catepsina B/metabolismo , Neoplasias/enzimología , Artritis/genética , Artritis/metabolismo , Artritis/patología , Amplificación de Genes/genética , Regulación de la Expresión Génica/genética , Humanos , Neoplasias/genética , Neoplasias/patología , Neoplasias/terapiaRESUMEN
Irreversible degradation of articular cartilage is a major feature of the arthritides, and its prevention is a therapeutic goal which has been difficult to achieve. Enzymes from the matrix metalloproteinase and ADAMTS (a disintegrin, a metalloproteinase, and thrombospondin motif) families are key mediators of cartilage extracellular matrix destruction. Inhibition of metalloproteinase activity is therefore a conceptually attractive therapeutic strategy, although clinical efficacy has not yet been demonstrated. This review outlines the biology behind metalloproteinases as drug targets in the arthritides, and poses important questions for the future design of such therapies.
Asunto(s)
Artritis/tratamiento farmacológico , Metaloproteinasas de la Matriz/fisiología , Inhibidores de Proteasas/farmacología , Proteínas ADAM/antagonistas & inhibidores , Proteínas ADAM/fisiología , Proteína ADAM17 , Animales , Artritis/enzimología , Artritis Experimental/tratamiento farmacológico , Artritis Experimental/enzimología , Cartílago Articular/efectos de los fármacos , Cartílago Articular/enzimología , Cartílago Articular/patología , Diseño de Fármacos , Evaluación Preclínica de Medicamentos , Proteínas de la Matriz Extracelular/metabolismo , Humanos , Inhibidores de la Metaloproteinasa de la Matriz , Ratones , Minociclina/farmacología , Minociclina/uso terapéutico , Inhibidores de Proteasas/uso terapéuticoRESUMEN
Pro-inflammatory cytokine such as interleukin (IL)-1beta causes inflammation of articular cartilage via induction of cyclooxygenase (COX)-2 expression. We investigated in this study the role of beta-catenin in the IL-1beta regulation of COX-2 expression in articular chondrocytes. IL-1beta increased expression of COX-2 and induced accumulation and nuclear translocation of transcriptionally competent beta-catenin. Inhibition of beta-catenin degradation by the treatment of cells with LiCl or proteasome inhibitor stimulated expression of COX-2, indicating that transcriptionally active beta-catenin is sufficient to induce COX-2 expression. This was demonstrated further by the observation that ectopic expression of transcriptionally competent beta-catenin stimulated expression of COX-2. Levels of beta-catenin and COX-2 protein were increased in osteoarthritic and rheumatoid arthritic cartilage, suggesting that beta-catenin may play a role in the inflammatory responses of arthritic cartilage. Taken together, our data suggest that accumulation of transcriptionally active beta-catenin contributes to the expression of COX-2 in articular chondrocytes.
Asunto(s)
Cartílago Articular/enzimología , Proteínas del Citoesqueleto/fisiología , Regulación Enzimológica de la Expresión Génica/fisiología , Isoenzimas/genética , Prostaglandina-Endoperóxido Sintasas/genética , Transactivadores/fisiología , Animales , Artritis/enzimología , Artritis/metabolismo , Cartílago Articular/citología , Cartílago Articular/efectos de los fármacos , Células Cultivadas , Ciclooxigenasa 2 , Proteínas del Citoesqueleto/metabolismo , Interleucina-1/farmacología , Conejos , Transactivadores/metabolismo , Activación Transcripcional/efectos de los fármacos , beta CateninaRESUMEN
In this paper we describe a method for validating therapeutic gene targets in arthritic disease. Ribozymes are catalytic oligonucleotides capable of highly sequence-specific cleavage of RNA. We designed ribozymes that cleave the mRNA encoding stromelysin, a matrix metalloproteinase implicated in cartilage catabolism. Ribozymes were initially screened in cultured fibroblasts to identify sites in the mRNA that were accessible for binding and cleavage. Accessible sites for ribozyme binding were found in various regions of the mRNA, including the 5' untranslated region, the coding region, and the 3' untranslated region. Several ribozymes that mediated sequence-specific and dose-dependent inhibition of stromelysin expression were characterized. Site selection in cell culture was predictive of in vivo bioactivity. An assay for measuring cartilage catabolism in rabbit articular cartilage explants was developed. Ribozymes inhibited IL-1-stimulated stromelysin mRNA expression in articular cartilage explants, yet failed to inhibit proteoglycan degradation. This indicated that up-regulation of stromelysin was not essential for IL-1-induced cartilage catabolism. Broad applications of this approach in therapeutic target validation are discussed.